Last Updated : August 13, 2024
Canada’s Drug Agency seeks patients’ perspectives to improve the relevance and quality of our reviews. Also, to enable those possibly affected by the reviews to have an opportunity to contribute to them. For reimbursement reviews and provisional funding algorithms, we invite patient groups to contribute relevant input and feedback.
To seek public reimbursement for a drug, a pharmaceutical company applies to Canada’s Drug Agency . We issue an open call for patient input. We send out notifications for these open calls every Thursday, through our Weekly Summary email newsletter. Calls for patient input are also highlighted on the open calls page of our website.
To participate:
Following our review and the expert committee deliberations, draft reimbursement recommendations are shared for feedback. New draft recommendations and open calls for feedback are highlighted in the Weekly Summary email newsletter.
To participate:
We issue a call for stakeholder input for all provisional funding algorithm projects. Open calls for input are highlighted in the Weekly Summary email newsletter.
To provide initial input at the outset of the provisional funding algorithm project:
We issue a call for feedback on all draft provisional funding algorithms. Open calls for feedback are highlighted in the Weekly Summary.
To provide feedback on a draft provisional funding algorithm:
If you have questions or need help to participate, please contact [email protected] or call us at 1 866 988 1444.
To learn more about our reimbursement review process, you can to the Procedures for Reimbursement Reviews.